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Introduction
Recent advances in the management of SJIA considered
the induction or maintenance of inactive disease according
to the JADAS 10-CRP (J10) or 27-CRP (J27) scoring sys-
tem [1,2]. The maintenance of efficacy of canakinumab
(CAN), a selective, human, anti-IL-1b monoclonal anti-
body, was demonstrated in the withdrawal phase of 2
phase III trials [3], but was not evaluated at the individual
level.
Objectives
To evaluate the maintenance of efficacy at the level of the
individual patient from Week 2 to 12, using the adapted
ACR-JIA response criteria (aACR) as well as J10 and J27
on the 12-week pooled data set (3 phase III studies).
Methods
For this post-hoc analysis of the CAN Phase III program
in SJIA, the change in disease states between Day(D) 15
and D85 of a total of 178 CAN-naïve patients was
assessed. Subjects were 2–19 years of age and had active
SJIA at enrollment. This shift analysis considered the
aACR response and certain disease activity states as
defined using J10 and J27: Inactive Disease (ID), Low
Disease Activity (LDA), Moderate Disease Activity
(MDA); High Disease Activity (HDA).
Results
J10 changes during the study period are provided in
Table 1. Results for the J27 were very similar to the J10
observations.
The D15-D85 aACR shift analyses, including only
patients who had a D15 and a D85 value, likewise indi-
cated that the majority of patients maintained or
improved their response: NR (n=32): 12.5% of patients
improved; aACR30 (n=14): 0.0% were maintained/
78.6% improved; aACR50 (n=21): 33.3% were main-
tained/42.9% improved; aACR70 (n=36): 25.0% were
maintained/58.3% improved; aACR90 (n=26): 30.8%
were maintained/57.7% improved; aACR100 (n=34):
82.4% were maintained.
Conclusion
The great majority of CAN patients either maintained or
improved their JADAS status or aACR response level
from week 2 to 12. These data confirm the consistent
maintenance of efficacy of CAN at the individual level
in the first 3 months, irrespective of the measure of
response, i.e. aACR criteria or JADAS-derived criteria,
and extend previous findings at the study group level.
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Table 1 J10 shift analysis table from D15 to D85*
N
(%)
Disease State at Day
15*
Disease state at Day 85*
ID LDA MDA HDA
ID 28 (100) 24
(85.7)
1 (3.6) 3 (10.7) 0 (0.0)




0 (0.0) 0 (0.0)





HDA 44 (100) 2 (4.5) 6 (13.6) 8 (18.2) 28
(63.6)
*Only patients with both a Day 15 and a Day 85 value are included
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